This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


The Impact of Atypical Antipsychotics on Weight Gain

Daniel E. Casey, MD; Dan W. Haupt, MD; John W. Newcomer, MD; David C. Henderson, MD; Michael J. Sernyak, MD; Michael Davidson, MD; Jean-Pierre Lindenmayer, MD; Steven V. Manoukian, MD, FACC; Mary Ann Banerji, MD; Harold E. Lebovitz, MD; and Charles H. Hennekens, MD

Published: May 1, 2004

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

The introduction of atypical antipsychotic medications has been a major advance in the treatment of schizophrenia. Besides a significantly lower risk for tardive dyskinesia and extrapyramidal side effects, they may have superior efficacy in treating negative symptoms, improving mood and cognition, and preventing relapse. However, these drugs can also cause some adverse effects, including weight gain and metabolic disturbances, which may increase risks of cardiovascular disease.’ ‹

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 65

Quick Links: